AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures

AstraZeneca isn't the first to attempt to reinvigorate its R&D organization. But the group's pure-pharma focus means it relies more heavily than most of its peers on the success of this organizational and cultural overhaul.